Your browser is no longer supported. Please, upgrade your browser.
Settings
JNCE Jounce Therapeutics, Inc. daily Stock Chart
JNCE [NASD]
Jounce Therapeutics, Inc.
Index- P/E12.81 EPS (ttm)0.62 Insider Own0.60% Shs Outstand34.05M Perf Week-16.86%
Market Cap260.05M Forward P/E- EPS next Y-2.72 Insider Trans-10.72% Shs Float30.53M Perf Month51.73%
Income21.80M PEG- EPS next Q-0.79 Inst Own75.90% Short Float7.00% Perf Quarter6.62%
Sales119.40M P/S2.18 EPS this Y297.10% Inst Trans-0.26% Short Ratio1.80 Perf Half Y57.80%
Book/sh3.74 P/B2.11 EPS next Y-15.30% ROA11.30% Target Price10.88 Perf Year121.63%
Cash/sh3.86 P/C2.04 EPS next 5Y- ROE13.50% 52W Range2.79 - 11.72 Perf YTD-9.62%
Dividend- P/FCF- EPS past 5Y43.00% ROI30.20% 52W High-32.68% Beta1.52
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low182.80% ATR0.91
Employees130 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)53.06 Volatility10.58% 12.64%
OptionableYes Debt/Eq0.00 EPS Q/Q-287.30% Profit Margin18.20% Rel Volume0.76 Prev Close7.96
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout0.00% Avg Volume1.19M Price7.89
Recom2.30 SMA202.58% SMA5030.93% SMA20032.62% Volume907,537 Change-0.88%
Sep-18-20Initiated ROTH Capital Buy $28
Mar-25-20Upgrade Raymond James Outperform → Strong Buy $11
Nov-14-18Downgrade JP Morgan Neutral → Underweight
Jun-28-18Initiated Raymond James Outperform
May-17-18Downgrade Wells Fargo Outperform → Market Perform
Apr-27-18Initiated H.C. Wainwright Buy $33
Sep-22-20 06:55AM  
Sep-02-20 04:01PM  
09:25AM  
Sep-01-20 10:24AM  
09:23AM  
08:30AM  
08:30AM  
Aug-07-20 06:30AM  
Aug-04-20 08:00AM  
Jul-31-20 08:00AM  
Jul-28-20 12:28PM  
Jul-05-20 11:13PM  
Jun-22-20 09:00AM  
Jun-10-20 08:00AM  
Jun-08-20 01:25PM  
Jun-04-20 08:00AM  
Jun-02-20 08:00AM  
May-15-20 08:00AM  
May-09-20 09:56AM  
May-06-20 08:30PM  
07:11AM  
06:30AM  
Apr-29-20 08:00AM  
Apr-21-20 08:14AM  
Feb-27-20 09:52AM  
06:30AM  
06:00AM  
Feb-26-20 08:00AM  
Feb-21-20 01:25PM  
07:50AM  
Feb-20-20 10:31AM  
Feb-06-20 08:00AM  
Jan-23-20 08:00AM  
Jan-09-20 08:00AM  
Jan-07-20 08:56AM  
Dec-20-19 11:30AM  
Dec-19-19 09:53PM  
03:00PM  
09:04AM  
08:45AM  
Dec-18-19 09:23AM  
Dec-13-19 08:39AM  
Dec-09-19 04:23PM  
Dec-06-19 09:28AM  
Dec-05-19 10:37AM  
08:32AM  
Dec-03-19 08:48AM  
Dec-02-19 09:46AM  
Nov-22-19 09:48AM  
Nov-21-19 12:15PM  
Nov-12-19 08:00AM  
Nov-11-19 10:50AM  
08:18AM  
Nov-07-19 07:55AM  
06:30AM  
Nov-05-19 08:05AM  
Oct-31-19 08:00AM  
Oct-29-19 09:28AM  
Oct-21-19 11:17AM  
Oct-01-19 06:01PM  
Sep-17-19 08:00AM  
Sep-05-19 11:22AM  
Aug-28-19 08:00AM  
Aug-21-19 08:37AM  
Aug-07-19 07:55AM  
06:30AM  
Jul-31-19 08:00AM  
Jul-24-19 11:34AM  
10:58AM  
07:08AM  
Jul-23-19 04:00PM  
Jul-12-19 04:52PM  
Jun-29-19 10:08PM  
Jun-18-19 08:00AM  
Jun-11-19 08:00AM  
May-23-19 09:23AM  
May-08-19 07:45AM  
06:30AM  
May-01-19 10:32AM  
08:00AM  
Apr-09-19 06:16PM  
Apr-03-19 08:02AM  
Apr-02-19 01:02PM  
Mar-12-19 12:59PM  
Mar-08-19 04:45AM  
Mar-06-19 06:30AM  
Mar-04-19 08:00AM  
Feb-28-19 08:00AM  
Feb-27-19 04:35PM  
Jan-29-19 05:19AM  
Jan-08-19 11:22AM  
Jan-03-19 08:00AM  
Jan-02-19 08:00AM  
Dec-23-18 06:07AM  
Nov-28-18 09:00AM  
Nov-13-18 08:00AM  
06:30AM  
Nov-10-18 12:20PM  
Nov-06-18 08:00AM  
Nov-05-18 10:30AM  
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duncan Barbara GayleDirectorSep 15Option Exercise4.2110,00042,10010,000Sep 16 06:43 PM
Duncan Barbara GayleDirectorSep 15Sale10.0010,000100,0000Sep 16 06:43 PM
Drapkin Kimberlee CCFO and TreasurerSep 01Sale8.067,20058,03261,708Sep 02 06:05 PM
Drapkin Kimberlee CCFO and TreasurerAug 18Sale4.717443,50468,908Aug 18 08:31 PM
Cole Hugh MChief Business OfficerAug 18Sale4.717443,50461,408Aug 18 08:29 PM
Trehu ElizabethChief Medical OfficerAug 17Sale4.864542,20677,377Aug 18 08:30 PM
Cole Hugh MChief Business OfficerAug 17Sale4.864542,20662,152Aug 18 08:29 PM
Drapkin Kimberlee CCFO and TreasurerAug 17Sale4.864542,20669,652Aug 18 08:31 PM
Drapkin Kimberlee CCFO and TreasurerAug 14Sale4.649844,56670,106Aug 18 08:31 PM
Cole Hugh MChief Business OfficerAug 14Sale4.649844,56662,606Aug 18 08:29 PM
Trehu ElizabethChief Medical OfficerAug 14Sale4.671,7288,07076,633Aug 18 08:30 PM
Trehu ElizabethChief Medical OfficerJan 07Sale7.782,62420,41556,565Jan 10 08:54 AM
Drapkin Kimberlee CCFO and TreasurerJan 07Sale7.782,62420,41544,390Jan 10 08:54 AM
Cole Hugh MChief Business OfficerJan 07Sale7.782,62420,41533,590Jan 10 08:53 AM
MURRAY RICHARD /CA/CEO and PresidentJan 07Sale7.787,15055,62787,360Jan 10 08:53 AM
Higgons John DuncanDirectorJan 06Sale8.111,50012,16512,013Jan 08 04:56 PM
MURRAY RICHARD /CA/CEO and PresidentDec 23Option Exercise0.4840,00019,200134,510Dec 26 05:08 PM
MURRAY RICHARD /CA/CEO and PresidentDec 23Sale8.3740,000334,80094,510Dec 26 05:08 PM